ÂÜÀòÂÒÂ×

Lindsey Baden, MD, serves as vice president of Clinical Research for Brigham and Women's Hospital. In his role as vice president, Baden provides comprehensive oversight of clinical research at the Brigham and is responsible for developing and implementing operational strategies, as well as building and maintaining the necessary infrastructure and resources in support of the clinical research mission and operational goals. He also oversees the Center for Clinical Investigation, serves as the primary liaison with Harvard Catalyst/Harvard Medical School, and has responsibility for increasing and maintaining research relationships across the Brigham, Mass General Brigham and the local collaborators.

Baden, an infectious diseases specialist, joined the Brigham in 1995 and has served in several critical leadership roles, including directing the Infectious Diseases Immunocompromised Host program at the Brigham and Dana-Farber, acting as program leader for the Clinical Research Centers of Harvard Catalyst and directing the Center for Clinical Investigation. A professor at Harvard Medical School and deputy editor of The New England Journal of Medicine, Baden is a highly respected clinician and clinical investigator. He has received continuous funding from the National Institutes of Health (NIH) throughout his career and is an expert in developing new therapeutics and vaccines. In response to the COVID-19 crisis, he was integral in the design and conduct of the pivotal NIH co-sponsored vaccine efficacy trials, Of note, he is the co-principal investigator for the phase 3 COVE study, which evaluated the mRNA-1273 (Moderna) vaccine candidate against COVID-19. This phase three trial, conducted in part at the Brigham, has led to the unprecedented rapid emergency use authorization, subsequent licensure and broad global use of this highly effective vaccine.